GOLDEN, CO--(Marketwire - December 09, 2008) - CeMines, Inc., a developer of innovative solutions for early stage detection of cancer, today announced it has entered into an agreement with Raritan, N.J.-based Ortho Clinical Diagnostics (“OCD”) to license certain CeMines Intellectual Property relating to blood-based testing for early stage lung cancer.
